Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of ALS

Cytokinetics, Inc., has received Orphan Drug Designation for its fast skeletal muscle troponin activator for ALS. A Phase 2 trial for CK-2017357 in ALS patients will begin in the second half of 2010. Orphan Drug Designation is a status granted by the FDA to novel drugs or biologics that treat a small number of people, and offers incentives such as marketing exclusivity, funding for clinical trials, study design assistance, and tax credits for clinical research.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail